ガバペンチンの市場規模、シェア、動向分析レポート：剤形別、タイプ別、用途別、流通チャネル別、地域別、セグメント予測、2025年～2030年

ガバペンチン市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のガバペンチン市場規模は2025～2030年にかけてCAGR 5.2%で拡大し、2030年には30億7,000万米ドルに達する見込みです。

この成長の背景には、神経障害性疼痛に対するガバペンチンの使用量の増加と、てんかんなどの関連疾患の世界の発生率の増加があります。その他の主要成長要因は、てんかんや神経因性疼痛のような状態になりやすい高齢者の増加です。

ジェネリック医薬品に対する需要の高まりは、大手ジェネリック医薬品メーカーにビジネス機会をもたらしているが、ジェネリック医薬品に対する嗜好性が高いため、中低所得国でのビジネス機会はより有利です。さらに、北米や欧州などの先進地域では、ガバペンチンなどのジェネリック医薬品の使用を促進することで、医療制度への負担を軽減するための施策変更が進められています。

ガバペンチンは主に、錠剤、カプセル剤、内服液剤の3つの剤形があります。カプセルは、主要ブランド製品の存在と入手のしやすさから、2022年に最大の市場シェアを占めました。ガバペンチンには中毒や過剰摂取のリスクがあることが判明したため、一部の国ではその使用を精査し、制限を設けています。ガバペンチンの長期的成長はこのような発見によって影響を受ける可能性があり、製薬メーカーはより安全で強力な鎮痛剤の開発に集中するようになる可能性があります。

北米は、ガバペンチンのような医薬品の採用を促進する医療制度が発達しているため、予測期間中は市場を独占すると予想されます。しかし、アジア太平洋などの他の地域は、主要なジェネリック医薬品の参入企業の存在や、アジア諸国で主に使用されている伝統的治療法よりも医薬品による治療法の採用に対する意識の高まりにより、より速い速度で成長しています。

ガバペンチン産業の主要競合企業には、Sun Pharmaceutical Industries Ltd.、Ascend Laboratories, LLC、Apotex Inc.、Teva Pharmaceutical Industries Ltd.、Arbor Pharmaceuticals, Inc.、Pfizer Inc.などがあります。ブランド製品の没落により、競合はジェネリック製品へとシフトしています。このため、参入企業や製品の市場が飽和状態になり、競争企業間の敵対関係が高まっています。

ガバペンチン市場レポートハイライト

• カプセルが市場を独占し、2024年には56.1%のシェアを占めます。これは、投与が容易であるため、小児や高齢者を含む患者にとって理想的であることに起因します。
• ガバペンチンのジェネリック医薬品が市場をリードし、2024年の売上シェアは90.1%でした。ジェネリック医薬品は、先発医薬品に代わる費用対効果の高い選択肢を提供し、より幅広い患者層へのアクセシビリティを拡大します。
• てんかん患者における発作管理に不可欠な抗けいれん薬としての有効性が実証されていることから、てんかんへの応用が2024年に49.9%の最大市場シェアを占めました。
• 病院薬局が市場を独占し、2024年には47.6%のシェアを占めました。これは、てんかんや神経障害性疼痛などの慢性疾患を治療するための重要な医療施設として機能しているためです。
• 北米のガバペンチン市場は2024年に33.7%の売上シェアを占め、世界市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ガバペンチン市場の変数、動向、範囲

• 市場系統の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 産業分析-ポーターのファイブフォース分析
  • PESTLE分析

第4章 ガバペンチン市場：剤形ビジネス分析

• 剤形市場シェア、2024年と2030年
• 剤形セグメントダッシュボード
• 市場規模と予測と動向分析、剤形別、2018～2030年
• 錠剤
• カプセル
• 経口液剤

第5章 ガバペンチン市場：タイプビジネス分析

• タイプ市場シェア、2024年と2030年
• タイプセグメントダッシュボード
• 市場規模と予測と動向分析、タイプ別、2018～2030年
• ジェネリック
• ブランド

第6章 ガバペンチン市場：用途ビジネス分析

• 用途市場シェア、2024年と2030年
• 用途セグメントダッシュボード
• 市場規模と予測と動向分析、用途別、2018～2030年
• てんかん
• 神経障害性疼痛
• むずむず脚症候群
• その他

第7章 ガバペンチン市場：流通チャネルビジネス分析

• 流通チャネル市場シェア、2024年と2030年
• 流通チャネルセグメントダッシュボード
• 市場規模と予測と動向分析、流通チャネル別、2018～2030年
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 ガバペンチン市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 国別、2018～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 国別、2018～2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • デンマーク
  • スウェーデン
• アジア太平洋
  • 国別、2018～2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • 国別、2018～2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 国別、2018～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Zydus Pharmaceuticals, Inc.
  • GLENMARK PHARMACEUTICALS LTD.
  • Sun Pharmaceutical Industries Ltd.
  • Ascend Laboratories LLC
  • Apotex Inc.
  • Teva Pharmaceutical Industries Ltd
  • Aurobindo Pharma
  • Amneal Pharmaceuticals LLC.
  • Cipla
  • BP Pharma
  • Assertio Holdings, Inc.
  • Arbor Pharmaceuticals, LLC（Azurity Pharmaceuticals, Inc.）
  • Pfizer Inc.

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Global gabapentin market, by region, 2018 - 2030 (USD Million)
• Table 4. Global gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 5. Global gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 6. Global gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 7. Global gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 8. North America gabapentin market, by country, 2018 - 2030 (USD Million)
• Table 9. North America gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 10. North America gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 11. North America gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 12. North America gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 13. U.S. gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 14. U.S. gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 15. U.S. gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 16. U.S. Gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 17. Canada gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 18. Canada gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 19. Canada gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 20. Canada gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 21. Mexico gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 22. Mexico gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 23. Mexico gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 24. Mexico gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 25. Europe gabapentin market, by country, 2018 - 2030 (USD Million)
• Table 26. Europe gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 27. Europe gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 28. Europe gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 29. Europe gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 30. UK gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 31. UK gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 32. UK gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 33. UK Gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 34. Germany gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 35. Germany gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 36. Germany gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 37. Germany gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 38. France gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 39. France gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 40. France gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 41. France Gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 42. Italy gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 43. Italy gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 44. Italy gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 45. Italy gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 46. Spain gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 47. Spain gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 48. Spain gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 49. Spain gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 50. Norway gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 51. Norway gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 52. Norway gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 53. Norway Gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 54. Denmark gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 55. Denmark gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 56. Denmark gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 57. Denmark gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 58. Sweden gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 59. Sweden gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 60. Sweden gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 61. Sweden gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 62. Asia Pacific gabapentin market, by country, 2018 - 2030 (USD Million)
• Table 63. Asia Pacific gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 64. Asia Pacific gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 65. Asia Pacific gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 66. Asia Pacific gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 67. Japan gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 68. Japan gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 69. Japan gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 70. Japan gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 71. China gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 72. China gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 73. China gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 74. China gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 75. India gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 76. India gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 77. India gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 78. India gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 79. Australia gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 80. Australia gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 81. Australia gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 82. Australia gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 83. South Korea gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 84. South Korea gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 85. South Korea gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 86. South Korea gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 87. Thailand gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 88. Thailand gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 89. Thailand gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 90. Thailand gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 91. Latin America gabapentin market, by country, 2018 - 2030 (USD Million)
• Table 92. Latin America gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 93. Latin America gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 94. Latin America gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 95. Latin America gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 96. Brazil gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 97. Brazil gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 98. Brazil gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 99. Brazil gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 100. Argentina gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 101. Argentina gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 102. Argentina gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 103. Argentina gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 104. Middle East & Africa Gabapentin market, by country, 2018 - 2030 (USD Million)
• Table 105. Middle East & Africa gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 106. Middle East & Africa gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 107. Middle East & Africa gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 108. Middle East & Africa gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 109. South Africa gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 110. South Africa gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 111. South Africa gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 112. South Africa gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 113. Saudi Arabia gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 114. Saudi Arabia gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 115. Saudi Arabia gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 116. Saudi Arabia gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 117. UAE gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 118. UAE gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 119. UAE gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 120. UAE gabapentin market, by distribution channel, 2018 - 2030 (USD Million)
• Table 121. Kuwait gabapentin market, by dosage form, 2018 - 2030 (USD Million)
• Table 122. Kuwait gabapentin market, by type, 2018 - 2030 (USD Million)
• Table 123. Kuwait gabapentin market, by application, 2018 - 2030 (USD Million)
• Table 124. Kuwait gabapentin market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Gabapentin market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Dosage form and type outlook (USD Million)
• Fig. 10 Application and distribution channel outlook (USD Million)
• Fig. 11 Competitive landscape
• Fig. 12 Gabapentin market dynamics
• Fig. 13 Gabapentin market: Porter's five forces analysis
• Fig. 14 Gabapentin market: PESTLE analysis
• Fig. 15 Gabapentin market: Dosage form segment dashboard
• Fig. 16 Gabapentin market: Dosage form market share analysis, 2024 & 2030
• Fig. 17 Tablet market, 2018 - 2030 (USD Million)
• Fig. 18 Capsule market, 2018 - 2030 (USD Million)
• Fig. 19 Oral solution market, 2018 - 2030 (USD Million)
• Fig. 20 Gabapentin market: Type segment dashboard
• Fig. 21 Gabapentin market: Type market share analysis, 2024 & 2030
• Fig. 22 Generic market, 2018 - 2030 (USD Million)
• Fig. 23 Branded market, 2018 - 2030 (USD Million)
• Fig. 24 Gabapentin market: Application segment dashboard
• Fig. 25 Gabapentin market: Application market share analysis, 2024 & 2030
• Fig. 26 Epilepsy market, 2018 - 2030 (USD Million)
• Fig. 27 Neuropathic pain market, 2018 - 2030 (USD Million)
• Fig. 28 Restless legs syndrome market, 2018 - 2030 (USD Million)
• Fig. 29 Others market, 2018 - 2030 (USD Million)
• Fig. 30 Gabapentin market: Distribution channel segment dashboard
• Fig. 31 Gabapentin market: Distribution channel market share analysis, 2024 & 2030
• Fig. 32 Hospital pharmacies market, 2018 - 2030 (USD Million)
• Fig. 33 Retail pharmacies market, 2018 - 2030 (USD Million)
• Fig. 34 Online pharmacies market, 2018 - 2030 (USD Million)
• Fig. 35 Gabapentin market revenue, by region
• Fig. 36 Regional marketplace: Key takeaways
• Fig. 37 Regional marketplace: Key takeaways
• Fig. 38 North America gabapentin market, 2018 - 2030 (USD Million)
• Fig. 39 U.S. country dynamics
• Fig. 40 U.S. gabapentin market, 2018 - 2030 (USD Million)
• Fig. 41 Canada country dynamics
• Fig. 42 Canada gabapentin market, 2018 - 2030 (USD Million)
• Fig. 43 Mexico country dynamics
• Fig. 44 Mexico gabapentin market, 2018 - 2030 (USD Million)
• Fig. 45 Europe gabapentin market, 2018 - 2030 (USD Million)
• Fig. 46 UK country dynamics
• Fig. 47 UK gabapentin market, 2018 - 2030 (USD Million)
• Fig. 48 Germany country dynamics
• Fig. 49 Germany gabapentin market, 2018 - 2030 (USD Million)
• Fig. 50 France country dynamics
• Fig. 51 France gabapentin market, 2018 - 2030 (USD Million)
• Fig. 52 Italy country dynamics
• Fig. 53 Italy gabapentin market, 2018 - 2030 (USD Million)
• Fig. 54 Spain country dynamics
• Fig. 55 Spain gabapentin market, 2018 - 2030 (USD Million)
• Fig. 56 Norway country dynamics
• Fig. 57 Norway gabapentin market, 2018 - 2030 (USD Million)
• Fig. 58 Sweden country dynamics
• Fig. 59 Sweden gabapentin market, 2018 - 2030 (USD Million)
• Fig. 60 Denmark country dynamics
• Fig. 61 Denmark gabapentin market, 2018 - 2030 (USD Million)
• Fig. 62 Asia Pacific gabapentin market, 2018 - 2030 (USD Million)
• Fig. 63 Japan country dynamics
• Fig. 64 Japan gabapentin market, 2018 - 2030 (USD Million)
• Fig. 65 China country dynamics
• Fig. 66 China gabapentin market, 2018 - 2030 (USD Million)
• Fig. 67 India country dynamics
• Fig. 68 India gabapentin market, 2018 - 2030 (USD Million)
• Fig. 69 Australia country dynamics
• Fig. 70 Australia gabapentin market, 2018 - 2030 (USD Million)
• Fig. 71 South Korea country dynamics
• Fig. 72 South Korea gabapentin market, 2018 - 2030 (USD Million)
• Fig. 73 Thailand country dynamics
• Fig. 74 Thailand gabapentin market, 2018 - 2030 (USD Million)
• Fig. 75 Latin America gabapentin market, 2018 - 2030 (USD Million)
• Fig. 76 Brazil country dynamics
• Fig. 77 Brazil gabapentin market, 2018 - 2030 (USD Million)
• Fig. 78 Argentina country dynamics
• Fig. 79 Argentina gabapentin market, 2018 - 2030 (USD Million)
• Fig. 80 MEA gabapentin market, 2018 - 2030 (USD Million)
• Fig. 81 South Africa country dynamics
• Fig. 82 South Africa gabapentin market, 2018 - 2030 (USD Million)
• Fig. 83 Saudi Arabia country dynamics
• Fig. 84 Saudi Arabia gabapentin market, 2018 - 2030 (USD Million)
• Fig. 85 UAE country dynamics
• Fig. 86 UAE gabapentin market, 2018 - 2030 (USD Million)
• Fig. 87 Kuwait country dynamics
• Fig. 88 Kuwait gabapentin market, 2018 - 2030 (USD Million)
• Fig. 89 Company categorization
• Fig. 90 Company market position analysis
• Fig. 91 Strategic framework

Gabapentin Market Growth & Trends:

The global gabapentin market size is expected to reach USD 3.07 billion by 2030, expanding at a CAGR of 5.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth can be attributed to the rising usage of gabapentin for neuropathic pain and the increasing incidence of associated diseases such as epilepsy globally. The other key growth driver is the rising geriatric population which is more to epilepsy and conditions such as neuropathic pain.

The growing demand for generics in the market is creating an opportunity for major generic players, however, the opportunity is more lucrative in the lower and middle-income nations due to the high preference for these drugs. Moreover, developed regions such as North America and Europe are further making policy changes to reduce the burden on the healthcare system by promoting the use of generics such as gabapentin.

Gabapentin is majorly available in three dosage forms, namely, tablet, capsule, and oral solution. The capsules segment held the largest market share in 2022, owing to the presence of major branded products and the ease of availability. Due to the discovery that gabapentin carries a risk of addiction and overdose, some nations have scrutinized its usage and placed limitations on it. Long-term growth for gabapentin may be impacted by such discoveries, which may push drugmakers to concentrate on creating safer and more potent painkillers.

North America is expected to dominate the market over the forecast period, due to a developed healthcare system that facilitates the adoption of drugs such as gabapentin. However, other regions such as Asia Pacific are growing at a faster rate attributable to the presence of key generic players and the rising awareness about the adoption of pharmaceutical treatments for diseases over traditional therapies, majorly used in Asian countries.

Some of the key competitors in the gabapentin industry include Sun Pharmaceutical Industries Ltd.; Ascend Laboratories, LLC; Apotex Inc.; Teva Pharmaceutical Industries Ltd.; Arbor Pharmaceuticals, Inc.; and Pfizer Inc. The downfall of branded products is leading to the shift of competition toward generic products. This is increasing the competitive rivalry due to increased marketplace saturation of players and products.

Gabapentin Market Report Highlights:

• Capsules dominated the market and accounted for a share of 56.1% in 2024. This is attributed to their ease of administration, which makes them ideal for patients, including children and the elderly.
• Generic gabapentin led the market with a revenue share of 90.1% in 2024. Generics provide a cost-effective alternative to branded medications, expanding accessibility for a wider patient demographic.
• Applications in epilepsy held the largest market share of 49.9% in 2024, owing to its proven efficacy as an anticonvulsant essential for seizure management in individuals with epilepsy.
• Hospital pharmacies dominated the market and accounted for a share of 47.6% in 2024, serving as key healthcare facilities for treating chronic conditions such as epilepsy and neuropathic pain.
• North America gabapentin market dominated the global market with a revenue share of 33.7% in 2024.

Table of Content

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Dosage Form
  • 1.2.2. Type
  • 1.2.3. Application
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Gabapentin Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Gabapentin Market: Dosage Form Business Analysis

• 4.1. Dosage Form Market Share, 2024 & 2030
• 4.2. Dosage Form Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
• 4.4. Tablet
  • 4.4.1. Tablet Market, 2018 - 2030 (USD Million)
• 4.5. Capsule
  • 4.5.1. Capsule Market, 2018 - 2030 (USD Million)
• 4.6. Oral Solution
  • 4.6.1. Oral Solution Market, 2018 - 2030 (USD Million)

Chapter 5. Gabapentin Market: Type Business Analysis

• 5.1. Type Market Share, 2024 & 2030
• 5.2. Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. Generic
  • 5.4.1. Generic Market, 2018 - 2030 (USD Million)
• 5.5. Branded
  • 5.5.1. Branded Market, 2018 - 2030 (USD Million)

Chapter 6. Gabapentin Market: Application Business Analysis

• 6.1. Application Market Share, 2024 & 2030
• 6.2. Application Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Epilepsy
  • 6.4.1. Epilepsy Market, 2018 - 2030 (USD Million)
• 6.5. Neuropathic Pain
  • 6.5.1. Neuropathic Pain Market, 2018 - 2030 (USD Million)
• 6.6. Restless Legs Syndrome
  • 6.6.1. Restless Legs Syndrome Market, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Gabapentin Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2024 & 2030
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Gabapentin Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Gabapentin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Regulatory Framework
    • 8.4.2.3. Competitive Insights
    • 8.4.2.4. U.S. Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Regulatory Framework
    • 8.4.3.3. Competitive Insights
    • 8.4.3.4. Canada Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Regulatory Framework
    • 8.4.4.3. Competitive Insights
    • 8.4.4.4. Mexico Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Gabapentin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Regulatory Framework
    • 8.5.2.3. Competitive Insights
    • 8.5.2.4. UK Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Regulatory Framework
    • 8.5.3.3. Competitive Insights
    • 8.5.3.4. Germany Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Regulatory Framework
    • 8.5.4.3. Competitive Insights
    • 8.5.4.4. France Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Regulatory Framework
    • 8.5.5.3. Competitive Insights
    • 8.5.5.4. Italy Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Regulatory Framework
    • 8.5.6.3. Competitive Insights
    • 8.5.6.4. Spain Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Norway
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Regulatory Framework
    • 8.5.7.3. Competitive Insights
    • 8.5.7.4. Norway Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Denmark
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Regulatory Framework
    • 8.5.8.3. Competitive Insights
    • 8.5.8.4. Denmark Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Sweden
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Regulatory Framework
    • 8.5.9.3. Competitive Insights
    • 8.5.9.4. Sweden Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Gabapentin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Regulatory Framework
    • 8.6.2.3. Competitive Insights
    • 8.6.2.4. Japan Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Regulatory Framework
    • 8.6.3.3. Competitive Insights
    • 8.6.3.4. China Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Regulatory Framework
    • 8.6.4.3. Competitive Insights
    • 8.6.4.4. India Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Regulatory Framework
    • 8.6.5.3. Competitive Insights
    • 8.6.5.4. South Korea Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Regulatory Framework
    • 8.6.6.3. Competitive Insights
    • 8.6.6.4. Australia Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Regulatory Framework
    • 8.6.7.3. Competitive Insights
    • 8.6.7.4. Thailand Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Gabapentin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Regulatory Framework
    • 8.7.2.3. Competitive Insights
    • 8.7.2.4. Brazil Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Regulatory Framework
    • 8.7.3.3. Competitive Insights
    • 8.7.3.4. Argentina Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Gabapentin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Regulatory Framework
    • 8.8.2.3. Competitive Insights
    • 8.8.2.4. South Africa Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Regulatory Framework
    • 8.8.3.3. Competitive Insights
    • 8.8.3.4. Saudi Arabia Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Regulatory Framework
    • 8.8.4.3. Competitive Insights
    • 8.8.4.4. UAE Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Regulatory Framework
    • 8.8.5.3. Competitive Insights
    • 8.8.5.4. Kuwait Gabapentin Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Zydus Pharmaceuticals, Inc.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. GLENMARK PHARMACEUTICALS LTD.
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Sun Pharmaceutical Industries Ltd.
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Ascend Laboratories LLC
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Apotex Inc.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Teva Pharmaceutical Industries Ltd
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Aurobindo Pharma
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Amneal Pharmaceuticals LLC.
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Cipla
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. B.P. Pharma
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives
  • 9.5.11. Assertio Holdings, Inc.
    • 9.5.11.1. Overview
    • 9.5.11.2. Financial Performance
    • 9.5.11.3. Product Benchmarking
    • 9.5.11.4. Strategic Initiatives
  • 9.5.12. Arbor Pharmaceuticals, LLC (Azurity Pharmaceuticals, Inc.)
    • 9.5.12.1. Overview
    • 9.5.12.2. Financial Performance
    • 9.5.12.3. Product Benchmarking
    • 9.5.12.4. Strategic Initiatives
  • 9.5.13. Pfizer Inc.
    • 9.5.13.1. Overview
    • 9.5.13.2. Financial Performance
    • 9.5.13.3. Product Benchmarking
    • 9.5.13.4. Strategic Initiatives